Macrocyclic GLP-1 Agonists Oral Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GLP-1 receptor agonists for treating type II diabetes mellitus are primarily injectable, which is inconvenient for patients, and there is a need for orally administered, potent GLP-1R agonists with a favorable toxicology and pharmacokinetic profile that supports once daily dosing.
Innovation Solution
Development of specific compounds, such as those described by the formula, which act as GLP-1R agonists, allowing for oral administration and potentially offering a favorable toxicology and pharmacokinetic profile suitable for once daily dosing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GLP-1R agonists are developed as injectable agents, then they can effectively enhance insulin secretion, but patient convenience deteriorates due to injection drawbacks such as pain, inconvenience, and injection site irritation
Solution Approach 1:
The patent introduces an oral formulation system as an intermediary between the GLP-1R agonist drug and the patient's digestive system. This includes specialized delivery vehicles, protective coatings, or absorption-enhancing mechanisms that allow the drug to survive gastric conditions and reach the bloodstream effectively, thereby eliminating the need for injections while maintaining therapeutic efficacy
Solution Approach 2:
The invention changes the administration route parameter from parenteral (injection) to oral. This fundamental parameter change requires modifying the drug's physical-chemical properties, stability profile, and formulation characteristics to enable oral delivery while preserving its ability to bind GLP-1 receptors and stimulate insulin secretion
2Reliability
If GLP-1R agonists are designed for potent activity, then therapeutic effectiveness improves, but toxicology profile may deteriorate
Solution Approach 1:
The patent applies local quality by designing the drug molecule to exhibit high selectivity and affinity specifically for the GLP-1 receptor subtype involved in insulin secretion. This targeted approach ensures potent therapeutic effect at the intended site of action while minimizing off-target interactions that could cause toxicity elsewhere in the body
Solution Approach 2:
The invention employs partial action by utilizing the endogenous GLP-1 signaling pathway's natural regulatory mechanisms. The drug mimics and enhances the body's own incretin system, which inherently limits excessive activation through feedback control, thereby achieving effective insulin secretion without the dangerous overstimulation that would cause toxicity
3Ease of operation
If GLP-1R agonists are formulated for once daily dosing, then patient compliance improves, but pharmacokinetic requirements become more stringent
Solution Approach 1:
The patent implements preliminary action through controlled-release formulation strategies. The drug is pre-loaded into delivery systems with sustained-release properties, such as matrix tablets, microspheres, or liposomal carriers, that gradually release the active ingredient over 24 hours, maintaining therapeutic levels throughout the dosing interval and enabling once-daily administration
Solution Approach 2:
The invention achieves continuity of useful action by designing the pharmacokinetic profile to maintain steady-state drug concentrations at the target site throughout the dosing interval. This involves optimizing absorption rate, distribution volume, metabolic clearance, and elimination half-life parameters to ensure continuous therapeutic effect without significant fluctuations that would require more frequent dosing
Data Source
AI summary
In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.